HomeCompareBNCHF vs PFE

BNCHF vs PFE: Dividend Comparison 2026

BNCHF yields 1100.72% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNCHF wins by $43717699.49M in total portfolio value
10 years
BNCHF
BNCHF
● Live price
1100.72%
Share price
$0.18
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43717699.54M
Annual income
$37,089,265,470,088.92
Full BNCHF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — BNCHF vs PFE

📍 BNCHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNCHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNCHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNCHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNCHF
Annual income on $10K today (after 15% tax)
$93,560.81/yr
After 10yr DRIP, annual income (after tax)
$31,525,875,649,575.58/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, BNCHF beats the other by $31,525,875,627,255.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNCHF + PFE for your $10,000?

BNCHF: 50%PFE: 50%
100% PFE50/50100% BNCHF
Portfolio after 10yr
$21858849.80M
Annual income
$18,544,632,748,173.82/yr
Blended yield
84.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BNCHF
No analyst data
Altman Z
2.3
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNCHF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNCHFPFE
Forward yield1100.72%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$43717699.54M$49.6K
Annual income after 10y$37,089,265,470,088.92$26,258.71
Total dividends collected$43217762.93M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BNCHF vs PFE ($10,000, DRIP)

YearBNCHF PortfolioBNCHF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$120,772$110,071.55$9,153$693.39+$111.6KBNCHF
2$1,371,610$1,242,384.20$8,593$849.25+$1.36MBNCHF
3$14,654,382$13,186,759.23$8,336$1,066.78+$14.65MBNCHF
4$147,351,522$131,671,333.43$8,437$1,384.80+$147.34MBNCHF
5$1,395,021,885$1,237,355,756.55$9,013$1,875.40+$1395.01MBNCHF
6$12,440,734,220$10,948,060,803.59$10,306$2,680.72+$12440.72MBNCHF
7$104,558,547,711$91,246,962,095.16$12,820$4,101.38+$104558.53MBNCHF
8$828,595,407,183$716,717,761,132.16$17,673$6,826.70+$828595.39MBNCHF
9$6,194,798,197,202$5,308,201,111,516.19$27,543$12,591.86+$6194798.17MBNCHF
10$43,717,699,541,095$37,089,265,470,088.92$49,560$26,258.71+$43717699.49MBNCHF

BNCHF vs PFE: Complete Analysis 2026

BNCHFStock

Benchmark Metals Inc., a junior resource company, engages in the identification, evaluation, acquisition, and exploration of mineral properties in Canada. The company explores for gold and silver deposits. It holds a 100% interest in the Lawyers Property project that consists of 46 contiguous mineral claims covering approximately 14,392 hectares located in British Columbia. The company was formerly known as Crystal Exploration Inc. and changed its name to Benchmark Metals Inc. in May 2018. The company was incorporated in 2010 and is headquartered in Edmonton, Canada.

Full BNCHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BNCHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNCHF vs SCHDBNCHF vs JEPIBNCHF vs OBNCHF vs KOBNCHF vs MAINBNCHF vs JNJBNCHF vs MRKBNCHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.